Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13269560 | 0.82 | OPRM1 (0.53) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3884950 | 0.82 | MEN1 (0.46) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4222736 | 0.77 | L3MBTL1 (0.64) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8913963 | 0.75 | POLB (0.59) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17118064 | 0.74 | SMYD3 (0.38) | GAAPOLBKDM4ELMNAMAPK1 | |
| SCHEMBL7453823 | 0.73 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL28536932 | 0.71 | TAAR1 (0.40) | ALDH1A1 | |
| SCHEMBL4052580 | 0.71 | OPRL1 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL1953270 | 0.70 | SMYD3 (0.35) | GAAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL3596622 | 0.70 | OPRM1 (0.53) | GAAALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550500-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-01-19 | — | — | US | disclosed |
| US-6960666-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-10-21 | — | — | US | disclosed |
| US-6784200-B2 | SUCH AS N-3-(CIS-2,3,3A,4,9,9A-HEXAHYDRO-1H-BENZ(F)ISOINDOL-2-YL)-N-PROP-1-YL-N'-3 -ACETYLPHENYLUREA FOR PREVENTION OF INFLAMMATORY DISEASES (ASTHMA AND ALLERGIES) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-01-08 | — | — | US | disclosed |
| US-6586446-B1 | Chemotaxic cytokine agonists or antagonists such as N(3-acetylphlenyl)-N'-(-2-((-3-((4-fluorophenyl)methyl)-8 -azabicyclo(3.2.1)oct-8-yl)methyl)-(2R)-1-cyclohexyl)urea, used as antiinflammatory agents for asthma or allergies | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | GAA 3965/4885ALDH1A1 964/4885MEN1 4366/4885 |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | GAA 3965/4885ALDH1A1 964/4885MEN1 4366/4885 |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, NR1I3 | GAA 3904/4885ALDH1A1 1875/4885MEN1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.